ADM Tronics Reports Third Quarter of Fiscal Year 2026 Results
Rhea-AI Summary
ADM Tronics (OTCQB:ADMT) reported third-quarter fiscal 2026 results for the period ended December 31, 2025, with quarterly revenue of $803,088 and nine-month revenue of $2,664,261. The company cited ongoing R&D on a non-invasive musculoskeletal pain therapy device and plans to submit a 510(k) when development is complete.
Quarter loss from operations was $84,441 and nine-month income from operations was $27,346. Complete results appear in the company Form 10-Q.
Positive
- Nine-month net income of $98,106 versus prior year loss of $18,196
- Nine-month revenue of $2,664,261, up 9% YoY
- Ongoing R&D toward a 510(k) submission for a musculoskeletal pain device
Negative
- Quarter net loss of $114,856
- Cost of sales rose to $1,534,675 for nine months, up ~24% YoY
- Quarter loss from operations of $84,441
NORTHVALE, NJ / ACCESS Newswire / February 13, 2026 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its third fiscal quarter ended December 31, 2025 of Fiscal Year 2026.
The upward trend in revenues, as reported in the Company's previous quarterly reports, continues for this third fiscal quarter of fiscal year ended March 31, 2026. For the nine months ended December 31, 2025 revenues increased
Revenues for the three months ended December 31, 2025 were
Revenues for the nine months ended December 31, 2025 were
Complete financial results are available in the Company's Quarterly Report on Form 10Q for December 31, 2025, available at www.sec.gov.
Financial Highlights
Three Months Ended | Nine Months Ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Net Revenues | $ | 803,088 | $ | 749,510 | $ | 2,664,261 | $ | 2,447,391 | ||||||||
Cost of Sales | $ | 530,592 | $ | 481,331 | $ | 1,534,675 | $ | 1,239,527 | ||||||||
Gross Profit | $ | 272,496 | $ | 268,179 | $ | 1,129,586 | $ | 1,207,864 | ||||||||
Total Operating Expenses | $ | 356,937 | $ | 357,448 | $ | 1,102,240 | $ | 1,178,710 | ||||||||
Income (loss) from operations | $ | (84,441 | ) | $ | (89,269 | ) | $ | 27,346 | $ | 29,154 | ||||||
Total other income (expense) | $ | (30,415 | ) | $ | (142,500 | ) | $ | 72,260 | $ | (45,850 | ) | |||||
Income (loss) before provision for income taxes | $ | (114,856 | ) | $ | (237,177 | ) | $ | 99,606 | $ | (16,696 | ) | |||||
Total provision (benefit) for income taxes | - | $ | 500 | $ | 1,500 | $ | 1,500 | |||||||||
Net income (loss) | $ | (114,856 | ) | $ | (237,677 | ) | $ | 98,106 | $ | (18,196 | ) | |||||
Basic and diluted per common share | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.00 | ) | ||||
Weighted average shares of common stock outstanding - basic and diluted | 67,588,492 | 67,588,492 | 67,588,492 | 67,588,492 | ||||||||||||
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered and ISO-13485 Certified medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com
Sign up for ADMT Investor News Updates emails by filling in the form at the bottom of the page at this link: https://admtronics.com/investor-relations/
Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.
Contact Information:
Andre DiMino
+12017676040
andre@admtronics.com
SOURCE: ADM Tronics Unlimited Inc.
View the original press release on ACCESS Newswire
FAQ
What were ADM Tronics (ADMT) revenues for Q3 fiscal 2026 and the nine months ended December 31, 2025?
Did ADM Tronics (ADMT) report a profit or loss for the quarter ended December 31, 2025?
What is the status of ADM Tronics (ADMT) FDA plans for its musculoskeletal pain device?
How did ADMT's cost of sales change in the nine months ended December 31, 2025?
Where can investors find ADM Tronics (ADMT) full quarterly financials for December 31, 2025?
What do ADM Tronics' (ADMT) nine-month operating results indicate about near-term performance?
